Clinical trial

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00084565

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention estramustine phosphate sodium Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record topotecan hydrochloride Normalized identity: topotecan hydrochlorideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2003-11-01

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

estramustine phosphate sodiumDRUG

paclitaxelDRUG · verified · RxNorm: paclitaxel

topotecan hydrochlorideDRUG · verified · RxNorm: topotecan hydrochloride

Sponsors & collaborators

Fox Chase Cancer Centerlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00084565 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.